

conditions and efficient management of ailments, difficulties in the treatment of chronic hepatitis C in elderly individuals are increasingly coming to the fore. This is attributable, at least in part, to liver fibrosis accelerating in parallel with age [11], as well as less tolerability and more side effects of combined interferon (IFN) and ribavirin in these patients [6,11,12].

These constraints notwithstanding, there is a pressing need for treatment of aged individuals with antiviral agents in order to prevent the development of cirrhosis and HCC and to promote better survival with an increased quality of life. When planning antiviral treatment of the elderly, weighing its merits against untoward effects, it is essential to understand the natural history of HCV infection in these patients. However, there have been virtually no reports on the natural history of HCV infection in older adults, nor are there any solid guidelines for antiviral treatment in these patients [13].

In the 42 years from 1964 to 2005, we have followed-up 332 patients who were persistently infected with HCV and had not received any antiviral treatment. They included the 120 patients with aspartate and alanine aminotransferase (ASAT and ALAT) levels  $\leq 40$  IU/l (group A) and the 212 with ASAT and/or ALAT  $\geq 41$  (group B), and were followed-up for 3 years or longer without receiving any antiviral treatment. It is hoped that the evolution of chronic hepatitis in these patients, with special reference to the baseline transaminase levels, will shed light on how they should be treated for the prevention of cirrhosis and HCC in the coming era of global longevity.

## Material and methods

### Patients

During 42 years, from 1964 through 2005, 7358 patients with HCV-RNA in the serum visited the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo. Of these patients, 843 (11.5%) were  $\geq 65$  years of age at presentation, and 512 (60.7% of the elderly) had not received antiviral agents or other drugs that might suppress the replication of HCV. In order to rule out cirrhosis, 180 patients with platelet counts  $< 120 \times 10^3/\text{mm}^3$  were excluded. The remaining 332 patients were classified into the 120 with ASAT and ALAT levels  $\leq 40$  IU/l (Group A) and the 212 with ASAT and/or ALAT levels  $\geq 41$  IU/l (group B); they included 22 patients (10.4%) with ASAT levels  $\leq 40$  IU/l and 18 (8.5%) with ALAT

levels  $\leq 40$  IU/l. Baseline transaminase levels were determined at least twice, 2–3 months apart, in the course of 6 months. The patients were followed-up for 3 years or longer without receiving any antiviral treatment, and tested monthly for liver function, HCV-RNA and  $\alpha$ -fetoprotein (AFP) or protein induced by the absence of vitamin K or antagonist-II (PIVKA-II). Screening for cirrhosis and HCC was carried out yearly using ultrasonography and/or computed tomography. Angiography was implemented when HCC was strongly suspected by imaging modalities. During follow-ups, herbal medicine (intravenous Stronger Neo-Minophagen C (SNMC) or oral Shousaikotou) and/or urso-deoxycholic acid was given to 51 (42.5%) patients in group A and 139 (65.6%) patients in group B. Three (2.5%) patients in group A and 24 (11.2%) patients in group B, in whom IFN was started after they had been followed-up for 3 years or longer, left the study cohorts at the initiation of treatment. Informed consent was obtained from each patient who participated in this study, and the protocol conformed to the ethics guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Human Research Committee of the institution.

### Markers of HCV infection

Qualitative assay for HCV-RNA was performed using polymerase chain reaction (PCR) with nested primers and the results were recorded as positive or negative, with the detection limit at 100 copies/ml. Quantification of HCV-RNA was carried out with the branched-DNA assay version 2.0 (Chiron Corp., Calif., USA), and the results were expressed in megaequivalents (MEq) per milliliter over a range from  $< 0.5$  to 120 MEq/ml.

### Statistical analysis

Since certain data in the analysis were regarded to comply with non-Gaussian distribution, categorical variables at baseline were compared with the Fisher exact test and numerical values were analyzed with the Mann-Whitney U-test and the Kruskal-Wallis test. Cumulative rates of cirrhosis, HCC, and death were calculated using the Kaplan-Meier technique, and differences between curves were evaluated by the log-rank test. A  $p$ -value  $< 0.05$  with the two-tailed test was considered significant. All the analyses were carried out using the computer program SPSS ver.11.0 (SPSS Inc., Ill., USA).

## Results

### *Treatment-naïve patients older than 65 years infected with HCV*

During the 42 years from 1964 through 2005, the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo admitted 332 patients aged 65 years or older with HCV who had not received any antiviral treatment, and in whom cirrhosis had not developed. In Table I we compare demographic, clinical, and virological characteristics between the 120 patients with baseline transaminase levels  $\leq 40$  IU/l and the 212 patients with levels  $\geq 41$  IU/l. ASAT and ALAT levels were higher, while platelet counts were lower in the patients with elevated transaminase levels compared with in patients without elevated transaminase levels.

When patients with baseline transaminase levels  $\leq 40$  IU/l were stratified by age, the median follow-up period was shorter in those aged 75–80 years than in those aged 65–69 or 70–74 years (4.5 versus 8.6 or 7.0 years,  $p=0.011$ ) (Table II). Although the baseline transaminase levels were within normal limits in all of them, the median ASAT level was higher in patients aged 70–74 years than in those aged 65–70 or 75–80 years (35 versus 27 or 28 IU/l,  $p=0.040$ ). In patients with baseline levels of both or either transaminase  $\geq 41$  IU/l, the median albumin level was lower in those aged 75–80 years than in those aged 65–69 or 70–74 years (3.9 versus 4.1 or 4.1 g/dl,  $p=0.005$ ) (Table III).

### *Development of cirrhosis and HCC*

Cirrhosis developed more frequently in elderly patients aged 65 years or older, with elevated transaminase levels at baseline, during follow-ups for longer than 3 years (Figure 1A). At 5 and 10 years of follow-up, cirrhosis developed in, respectively, 26% and 27% of the patients with the baseline transaminase levels  $\geq 41$  IU/l in contrast to only

4% and 13% of the patients with levels  $\leq 40$  IU/l ( $p<0.001$ ). Likewise, HCC developed more frequently in elderly patients with elevated transaminase levels at baseline (Figure 1B). At 5 and 10 years of follow-up, HCC developed in, respectively, 22% and 26% of the patients with the baseline transaminase levels  $\geq 41$  IU/l, contrasting with only 3% and 5% of the patients with levels  $\leq 40$  IU/l ( $p<0.001$ ).

Development of cirrhosis is compared between patients with and without elevated transaminase levels at baseline who were stratified by age (Figure 2). Cirrhosis developed more frequently in the patients with elevated transaminase levels than in those without elevated transaminase levels who were aged 65–69 years ( $p<0.001$ ). In patients aged 70–74 years, cirrhosis tended to occur more often in those with elevated transaminase levels than in those without elevated transaminase levels during 5 years (27% versus 0%), but the difference fell short of being significant owing to the small number of patients in both groups.

Likewise, development of HCC is compared between patients with and those without elevated transaminase levels at baseline who were stratified by age (Figure 3). HCC developed more frequently in the patients with elevated transaminase levels than in those without elevated transaminase levels who were aged 65–69 years ( $p=0.001$ ). In patients aged 70–74 and 75–80 years, HCC tended to occur more often in those with elevated transaminase levels than in those without elevated transaminase levels during 5 years (20% versus 5% and 19% versus 0%, respectively), but the difference was not significant, owing to the small number of patients in both groups.

### *Influence of gender on the development of cirrhosis and HCC*

Figure 4 shows a comparison of the development of cirrhosis and HCC between 155 male and 177

Table I. Characteristics of patients with HCV-RNA aged 65 years or older with or without elevated transaminase (ASAT and ALAT) levels.

| Features                                | $\leq 40$ IU/ml<br>( $n=120$ ) | $\geq 41$ IU/l<br>( $n=212$ ) | Differences<br>$p$ -value |
|---|--------------------------------|-------------------------------|---------------------------|
| Men                                     | 51 (42.5%)                     | 104 (49.1%)                   | 0.513                     |
| Follow-up (years)                       | 7.8 (3–31.5)                   | 8.7 (3–18.9)                  | 0.181                     |
| ASAT (IU/l)                             | 23 (6–40)                      | 76 (27–496)                   | <0.001                    |
| ALAT (IU/l)                             | 28 (11–40)                     | 63 (22–411)                   | <0.001                    |
| Albumin (g/dl)                          | 4.1 (2.4–4.9)                  | 4.1 (3.2–5.3)                 | 0.189                     |
| Platelets ( $\times 10^3/\text{mm}^3$ ) | 184 (120–343)                  | 173 (120–313)                 | 0.001                     |
| HCV RNA (MEq/ml)                        | 4.5 (<0.5–120)                 | 5.6 (<0.5–49)                 | 0.168                     |
| HCV genotypes<br>(1b:2a:2b:ND)          | 85:20:3:7                      | 176:28:12:9                   | 0.970                     |

Abbreviations: HCV = hepatitis C virus; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase; MEq = megaequivalents; ND = not determined. Data are expressed as the number (%) or the median with the range in parentheses.

Table II. Characteristics of patients aged 65 years or older with HCV-RNA and without elevated baseline transaminase levels (ASAT and ALAT  $\leq 40$  IU/l) stratified by the age.

| Features                                | 65-69 years<br>(n=79 (65.8%)) | 70-74 years<br>(n=25 (20.8%)) | 75-80 years<br>(n=16 (13.3%)) | Differences<br>p-value |
|---|-------------------------------|-------------------------------|-------------------------------|------------------------|
| Men                                     | 29 (36.7%)                    | 11 (44.0%)                    | 11 (68.8%)                    | 0.062                  |
| Follow-up (years)                       | 8.6 (3-31.5)                  | 7.0 (3-12.6)                  | 4.5 (3-17.6)                  | 0.011                  |
| ASAT (IU/l)                             | 27 (11-39)                    | 35 (16-40)                    | 28 (15-40)                    | 0.004                  |
| ALAT (IU/l)                             | 22 (6-40)                     | 25 (9-40)                     | 22 (9-37)                     | 0.604                  |
| Albumin (g/dl)                          | 4.1 (3.2-4.9)                 | 4.1 (3.0-4.4)                 | 4.0 (2.4-4.5)                 | 0.247                  |
| Platelets ( $\times 10^3/\text{mm}^3$ ) | 193 (120-298)                 | 177 (120-343)                 | 182 (120-263)                 | 0.408                  |
| HCV RNA (MEq/ml)                        | 4.2 (<0.5-34.6)               | 6.5 (<0.5-120)                | 4.0 (<0.5-17.1)               | 0.181                  |
| HCV genotypes<br>(1b:2a:2b:ND)          | 51:19:2:4                     | 21:1:1:1                      | 13:0:0:2                      | 0.074                  |

Abbreviations: HCV = hepatitis C virus; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase; MEq = megaequivalents; ND = not determined. Data are expressed as the number (%) or the median with the range in parentheses.

female patients aged 65 years or older. Cirrhosis tended to occur more frequently in male than in female patients. There were marked gender differences in the development of HCC. At 5 and 10 years of follow-up, HCC occurred more frequently in men than in women (18% and 25% versus 9% and 9%, respectively,  $p=0.033$ ).

#### Complications and death in patients with the baseline transaminase levels $\leq 40$ IU/l and $\geq 41$ IU/l

Of the 120 patients with baseline transaminase levels  $\leq 40$  IU/l, 33 (27.5%) developed complications during follow-up (hypertension in 9 (27%), diabetes in 7 (21%), both complications in 1 (3%), pulmonary disease in 4 (12%), heart disease in 4 (12%), and other illnesses in the remaining 8 (24%). At 5, 10, and 15 years of follow-up, respectively, death occurred more frequently in the patients with complications than in those without complications (10%, 18%, and 45% versus 0%, 5%, and 5%,  $p=0.015$ ) (Figure 5).

Among 9 of the 120 (7.5%) patients who died, liver disease was the cause of death in only one. Of

the remaining 8 (89%) patients, 4 died of heart failure or infarction, and one each of pneumonia, cerebral hemorrhage, renal insufficiency, and decrepitude. Death was more frequent in the patients aged  $\geq 70$  years than in those aged  $< 70$  years at presentation ( $p=0.006$ ) (Figure 6).

Complications and death in patients with the baseline transaminase levels  $\geq 41$  IU/l

Of the 212 patients with baseline transaminase levels  $\geq 41$  IU/l, 83 (39.2%) developed complications during follow-up (hypertension in 18 (22%), diabetes in 23 (28%), both complications in 10 (12%), extrahepatic malignancies in 12 (15%), and other diseases in the remaining 20 (24%). There were no differences in the frequency of death between the patients with and those without complications, however (Figure 7).

Among 34 of the 212 (14.0%) patients who died, liver disease was the most frequent cause of death and occurred in 20 (59%); the frequency was higher than that (11% (1/9)) in the patients with transaminase levels  $\leq 40$  IU/l at baseline ( $p=0.021$ ). There were no differences in the frequency of death among

Table III. Characteristics of patients with HCV-RNA aged 65 years or older and with elevated baseline transaminase levels (ASAT and/or ALAT  $\geq 41$  IU/l) stratified by the age.

| Features                                | 65-69 years<br>(n=140 (66.0%)) | 70-74 years<br>(n=48 (22.6%)) | 75-80 years<br>(n=24 (11.3%)) | Differences<br>p-value |
|---|--------------------------------|-------------------------------|-------------------------------|------------------------|
| Men                                     | 63 (45.0%)                     | 25 (52.1%)                    | 16 (66.7%)                    | 0.707                  |
| Follow-up (years)                       | 9.0 (3-18.9)                   | 8.4 (3-17.2)                  | 7.7 (3-14.7)                  | 0.061                  |
| ALAT (IU/l)                             | 82 (28-496)                    | 74 (27-440)                   | 64 (30-269)                   | 0.959                  |
| ASAT (IU/l)                             | 67 (22-411)                    | 67 (34-309)                   | 71 (35-172)                   | 0.201                  |
| Albumin (g/dl)                          | 4.1 (3.2-5.3)                  | 4.1 (3.4-4.6)                 | 3.9 (3.4-4.7)                 | 0.005                  |
| Platelets ( $\times 10^3/\text{cm}^3$ ) | 171 (120-313)                  | 180 (120-289)                 | 157 (120-263)                 | 0.398                  |
| HCV RNA (MEq/ml)                        | 5.9 (<0.5-44.8)                | 5.6 (<0.5-30.0)               | 3.0 (<0.5-49.0)               | 0.251                  |
| HCV genotypes<br>(1b:2a:2b:ND)          | 121:19:8:6                     | 37:7:4:1                      | 18:2:0:2                      | 0.294                  |

Abbreviations: HCV = hepatitis C virus; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase; MEq = megaequivalents; ND = not determined.




Figure 1. Development of cirrhosis (A) and HCC (hepatocellular carcinoma) (B) in patients over 65 years of age with chronic hepatitis C who were followed-up without receiving antiviral treatment. Patients with and without elevated baseline transaminase levels are compared.

the patients in distinct age groups who had elevated baseline transaminase levels at baseline (Figure 8).

**Discussion**

The World Health Organization defines elderly individuals as those aged  $\geq 65$  years. In general, IFN is indicated for patients under 65 years of age, in view of frequent side effects and safety precautions. HCC develops increasingly with age and in the majority after 65 years, and in Japan approximately




Figure 2. Development of cirrhosis in patients of more than 65 years of age with chronic hepatitis C who were followed-up without receiving antiviral treatment. Patients in different age groups are compared between those with and those without elevated transaminase levels.

For personal use only.




Figure 3 (Continued)




Figure 4. Development of cirrhosis (A) and HCC (hepatocellular carcinoma) (B) in patients over 65 years of age with chronic hepatitis C who were followed-up without receiving antiviral treatment. Male and female patients are compared.

30,000 patients infected with HCV die yearly [14]. Furthermore, HCC is steadily increasing in the United States, and the incidence is expected to double or triple in the next two decades [15]. Hence, HCV carriers aged 65 years or older should be given IFN treatment, which is proven to be efficacious in preventing the development of HCC [16,17]. Previously, we have evaluated the efficacy and safety of IFN monotherapy in patients aged 65 years or older [18]. Of the 84 patients studied, the sustained virological response was reached in 30 (36%), while

Figure 3. Development of hepatocellular carcinoma (HCC) in patients over 65 years of age with chronic hepatitis C who were followed-up without receiving antiviral treatment. Patients in different age groups are compared between those with and those without elevated transaminase levels.




Figure 5. Deceased patients without elevated baseline transaminase levels (ASAT and ALAT <40 IU/l). Patients with and without complications other than liver disease are compared.

IFN was discontinued owing to adverse events in 11 (13%). Remarkably, the sustained virological response to combined IFN and ribavirin was comparable between the 66 patients aged  $\geq 60$  years and the 154 aged <60 years (31.8% versus 38.3%), although ribavirin had to be discontinued more frequently in the older patients (33.3% versus 20.8%,  $p < 0.05$ ) [19].

HCV spread widely in Japan around the end of World War II, at least 20 years earlier than in the other countries [4,14]. As a consequence, patients given combined IFN and ribavirin are 10–15 years




Figure 7. Deceased patients without elevated baseline transaminase levels (ASAT and ALAT <40 IU/l). Patients with and without complications other than liver disease are compared.

older than those in Western countries [20–22]. Throughout the world, there are increasing numbers of individuals who are infected with HCV and entering the elder years. By the year 2010, the number of the elderly infected with HCV is estimated to account for 0.48 (54%) of the entire 0.89 million infected in Japan, and that in the United States for 0.78 (22%) of the 3.61 million [2–4]. These numbers will continue to increase for some time thereafter. As sequelae to this, cirrhosis and HCC will continue to increase, demanding higher medical costs. In the USA already, HCV-related




Figure 6. Deceased patients with elevated baseline transaminase levels (ASAT and/or ALAT >41 IU/l). Patients in the different age groups are compared.




Figure 8. Deceased patients with elevated baseline transaminase levels (ASAT and/or ALAT >41 IU/l). Patients in the different age groups are compared.

end-stage liver disease is the leading cause of orthotopic liver transplantation [23]. This background demands that immediate measures should be taken to prevent fibrosis developing in the elderly with chronic hepatitis C by initiating the appropriate treatment; pegylated IFN combined with ribavirin can eliminate HCV efficiently [24,25].

Management of antiviral treatment in the elderly, however, is not without difficulties. Discontinuation of therapy or dose reduction was required frequently in the Japanese patients older than 60 years with chronic hepatitis C [21]. It is obvious that antiviral treatment needs to be administered with caution in aged patients with chronic hepatitis C, with the indication restricted to those who are likely to derive benefit from it. Early virological response at 12 weeks of treatment is predictive of sustained virological response [26]. The influence of HCV genotypes on the response to combined therapy, which increases with age [27], would have to be taken into consideration, also. In the Japanese patients infected with HCV genotype 1b, substitutions of amino acids at positions 70 and 91 are associated with a better response to combined treatment [28]. In view of the more frequent and serious side effects in elderly patients, these predictors would need to be taken into account when deciding whether to continue or discontinue combined treatment with IFN and ribavirin in elderly patients with chronic hepatitis C.

In order to plan the treatment of elderly patients, the natural history of HCV infection in these patients needs to be elucidated, which has not been done as yet. In the present study, we have followed-up treatment-naïve patients aged  $\geq 65$  years without antiviral treatment for more than 3 years. None of them had cirrhosis at baseline. They were stratified by baseline transaminase levels  $\leq 40$  IU/l (group A ( $n=120$ )) and  $\geq 41$  IU/l (group B ( $n=212$ )) and classified further into the three age groups, 65–69, 70–74, and 75–85 years. Cirrhosis and HCC developed more frequently in the patients in group B than those in group A ( $p < 0.001$  for both). Of the patients aged 65–69 years at entry, in particular, cirrhosis and HCC developed more frequently in group B than in group A ( $p < 0.001$  and  $p = 0.001$ , respectively). Liver-related causes of death were more common in group B than in group A (20/34 (59%) versus 1/9 (11%),  $p < 0.05$ ), and HCC developed more frequently in men than in women ( $p = 0.021$ ).

Despite the progression of fibrosis that is accelerated with age [6], liver-related deaths were infrequent in patients with normal baseline transaminase levels and much less often than in those with elevated baseline transaminase levels (1/120 (0.8%) versus 20/212 (9.4%),  $p = 0.002$ ). Development of cirrhosis or HCC was no different between patients

in groups A and B who were aged 70 years or older at entry. Taken altogether, elderly patients with elevated transaminase levels who are younger than 70 years would be the best candidates for antiviral treatment. They would need to be treated, even when side effects appear, by modifying the doses of IFN and ribavirin. In contrast, antiviral treatment may not be necessary for elderly patients with normal ALAT levels, or can be discontinued in these patients when side effects emerge.

There has been some controversy over antiviral treatment for elderly patients with chronic hepatitis C, and no specific guidelines have been drawn up so far [29]. The sustained virological response to antiviral treatment in aged patients is reported to be either poorer than [30–32] or comparable with that in younger patients [19,33]. The difference is most likely ascribed to careful selection of the aged patients who would benefit from treatment [13]. Based on the natural history of elderly patients with chronic hepatitis C described herein, those with elevated transaminase levels would need treatment to prevent progression to cirrhosis and HCC, while others with normal levels may not require treatment. It is to be hoped that the results in this study might be of help in planning a reasonable treatment strategy towards the longevity, without development of cirrhosis or HCC, in elderly patients with chronic hepatitis C, whose numbers are expected to increase progressively in the foreseeable future.

#### Acknowledgements

This work was supported in part by grants from the Ministry of Health, Labor, and Welfare of Japan.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

#### References

- [1] Cohen J. The scientific challenge of hepatitis C. *Science* 1999;285:26–30.
- [2] Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. *Inter-virology* 2004;47:32–40.
- [3] Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. *Am J Public Health* 2000;90:1562–9.
- [4] Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med* 2006;144:705–14.
- [5] Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *Irish Hepatology Research Group. N Engl J Med* 1999;340:1228–33.

- [6] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 1997;349:825–32.
- [7] Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med* 1999;341:866–70.
- [8] Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. *Gastroenterology* 1995;108:1088–96.
- [9] Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbo J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. *Am J Gastroenterol* 1997;92:1130–4.
- [10] Pageaux GP, Ducos J, Mondain AM, Costes V, Picot MC, Perrigault PF, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. *Liver Transpl Surg* 1997;3:501–5.
- [11] Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. *Gut* 2002;51:248–52.
- [12] Kumada T, Toyoda H, Honda T, Kuzuya T, Katano Y, Nakano I, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. *Intervirol* 2006;49:112–8.
- [13] Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. *Clin Infect Dis* 2005;41:1606–12.
- [14] Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. *Intervirol* 2006;49:7–17.
- [15] El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann Intern Med* 2003;139:817–23.
- [16] Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. *J Med Virol* 2007;79:1485–90.
- [17] Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 1999;29:1124–30.
- [18] Koyama R, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. *Intervirol* 2006;49:121–6.
- [19] Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, et al. Efficacy of ribavirin plus interferon-alpha in patients aged (60 years with chronic hepatitis C. *J Gastroenterol Hepatol* 2007;22:989–95.
- [20] Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 1998;339:1493–9.
- [21] Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. *Hepatology* 2006;43:54–63.
- [22] Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet* 1998;352:1426–32.
- [23] Verna EC, Brown RS Jr. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted? *Clin Liver Dis* 2008;12:637–59.
- [24] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–82.
- [25] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–65.
- [26] Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003;38:645–52.
- [27] Antonucci G, Longo MA, Angeletti C, Vairo F, Oliva A, Comandini UV, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 years. *Am J Gastroenterol* 2007;102:1383–91.
- [28] Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 2007;79:1686–95.
- [29] Wright TL. Treatment of patients with hepatitis C and cirrhosis. *Hepatology* 2002;36:S185–94.
- [30] Floreani A, Minola E, Carderi I, Ferrara F, Rizzotto ER, Baldo V. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? *J Am Geriatr Soc* 2006;54:549–50.
- [31] Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. *Arch Intern Med* 1998;158:177–81.
- [32] Hiramatsu N, Oze T, Tsuda N, Kurashige N, Koga K, Toyama T, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? *Hepatol Res* 2006;35:185–9.
- [33] Tsui JJ, Currie S, Shen H, Bini EJ, Brau N, Wright TL. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. *Dig Dis Sci* 2008;53:809–14.





Contents lists available at ScienceDirect

Journal of Clinical Virology

journal homepage: [www.elsevier.com/locate/jcv](http://www.elsevier.com/locate/jcv)



## Case report

# Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

Fumitaka Suzuki<sup>a,\*</sup>, Yoshiyuki Suzuki<sup>a</sup>, Norio Akuta<sup>a</sup>, Hitomi Sezaki<sup>a</sup>, Hiromi Yatsuji<sup>a</sup>, Yasuji Arase<sup>a</sup>, Miharuru Hirakawa<sup>a</sup>, Yusuke Kawamura<sup>a</sup>, Tetsuya Hosaka<sup>a</sup>, Masahiro Kobayashi<sup>a</sup>, Satoshi Saito<sup>a</sup>, Kenji Ikeda<sup>a</sup>, Mariko Kobayashi<sup>b</sup>, Sachiyo Watahiki<sup>b</sup>, Rie Mineta<sup>b</sup>, Satomi Iwasaki<sup>b</sup>, Hiromitsu Kumada<sup>a</sup>

<sup>a</sup> Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

<sup>b</sup> Research Institute for Hepatology, Toranomon Branch Hospital, Kawasaki, Japan

## ARTICLE INFO

### Article history:

Received 22 April 2009

Received in revised form 10 July 2009

Accepted 25 September 2009

### Keywords:

Hepatitis C virus

Protease inhibitor

Telaprevir

Sustained virological response

## ABSTRACT

Here, we describe for the first time a case of sustained virological response (SVR) achieved in a patient with chronic hepatitis C (CH-C) by monotherapy with a NS3-4A protease inhibitor, telaprevir, without interferon therapy. A 59-year-old treatment-naïve Japanese man was enrolled in a phase II trial of telaprevir by repeat oral administration at a dose of 750 mg every 8 h for 24 weeks. At the start of treatment, he exhibited a low-level viremia with genotype 1b of the hepatitis C virus (HCV). After the first week of treatment with telaprevir, serum HCV RNA was undetectable, and negativity remained until the end of treatment. Moreover, he was evaluated as having a SVR after the post-treatment 24-week follow-up program. Two characteristics may explain the strong antiviral activity of telaprevir in the present case. First, although pre-treatment PCR-direct sequencing and cloning for the N-terminal in the NS3 region showed a protease inhibitor-resistant variant (T54A) in 1 of 32 independent clones, the T54A substitution has only a low-level resistance to protease inhibitors and his viral load was low. Second, when compared to a consequence sequence of 35 treatment-naïve patients with HCV genotype 1b, R130K and Q195K substitutions were unique to the present case. Although it is presently unknown whether the R130K and Q195K substitutions are related to SVR, this case suggests that long-term telaprevir monotherapy may be effective in CH-C patients with genotype 1 and a low viral load.

© 2009 Elsevier B.V. All rights reserved.

## 1. Introduction

The goals of antiviral treatment in patients with chronic hepatitis C (CH-C) are long-lasting eradication of the virus and a decrease in disease-related hepatic mortality. Standard treatment uses a combination of pegylated interferon and ribavirin (PEG-IFN-RBV), which provides a sustained virological response (SVR) rate of over 50%.<sup>1,2</sup> In Japan, approximately 70% of patients with CH-C are infected with genotype 1b, and those with a high titer of genotype 1b ( $\geq 100$  KIU/mL [Amplicor; Roche Diagnostics K.K. Tokyo, Japan]) have lower rates of SVR (<50%), even on 48 weeks of PEG-IFN-RBV combination therapy.<sup>3</sup> Further, although treatment for CH-C is currently based on interferon (IFN), use of this agent is associated with serious adverse effects in some patients, such as mental disorders, apathy, and laboratory abnormalities.<sup>1,2,4</sup> Moreover, most CH-C patients in Japan over 70 years of age cannot receive IFN ther-

apy due to either or both co-morbidities and the risk of adverse effects. For these reasons, a new treatment strategy is needed for patients with CH-C that displays high SVR rates and a favorable side-effect profile.

One recently introduced treatment strategy for CH-C is inhibition of the NS3-4A protease in the HCV polyprotein. Potential inhibitors include telaprevir (VX-950; MP-424; Mitsubishi Tanabe Pharma Co., Osaka, Japan), which has been selected as a clinical therapy candidate for the treatment of CH-C.<sup>5</sup> In some patients with genotype 1 and a high viral load, however, the efficacy of telaprevir monotherapy was limited, and combination therapy of telaprevir plus PEG-IFN-RBV is now standard.<sup>6–10</sup> On this background, we therefore report here for the first time a patient with CH-C who achieved a SVR following monotherapy with telaprevir.

## 2. Case report

A 59-year-old Japanese man was admitted to Toranomon Hospital, Tokyo in July 2007 following a positive result for HCV RNA at general check-up. Laboratory tests before treatment showed mild

\* Corresponding author. Tel.: +81 44 877 5111; fax: +81 44 860 1623.  
E-mail address: [fumitakas@toranomon.gr.jp](mailto:fumitakas@toranomon.gr.jp) (F. Suzuki).




Fig. 1. Clinical course during and after 24 weeks of telaprevir monotherapy.

elevation of ALT (46 IU/L), and persistent HCV infection with genotype 1b and low-level viremia (<5 Log IU/mL [COBAS TaqMan HCV test, Roche Diagnostics K.K. Tokyo]) that continued to remain low until the start of treatment. He was diagnosed with CH-C by peritoneoscopy and liver biopsy (mild hepatitis [A1] and moderate fibrosis [F2]) at our hospital in February 2008. He had not received IFN therapy or any other antiviral drugs, and was enrolled in a phase II trial of telaprevir. Written informed consent was obtained, and the study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki. Treatment with telaprevir was started in March 2008, at which time serum HCV RNA was 3.9 Log IU/mL. Treatment was by repeat oral administration at a dose of 750 mg every 8 h for 24 weeks. Serum HCV RNA was undetectable after the first week and remained negative until the end of treatment (September 2008), and moreover remains undetectable as of March 2009. He was evaluated as having a SVR after the post-treatment 24-week follow-up program (Fig. 1).

The genome sequence for the N-terminal 609 nucleotides (203 amino acids) in the NS3 region of HCV isolates from the patient was analyzed before treatment with telaprevir. HCV RNA was extracted from 100 µL of serum and the

nucleotide sequences were determined by direct sequencing and cloning. The primers used to amplify the NS3 region were NS3-F1 (5'-ACACCGCGCGTGTGGGGACAT-3'; nucleotides 3295-3316) and NS3-AS2 (5'-GCTCTTGGCGTGCCAGTGGGA-3'; nucleotides 4040-4019) as the first (outer) primer pair and NS3-F3 (5'-CAGGGGTGGCGGCTCCTT -3'; nucleotides 3390-3407) and NS3-AS2 as the second (inner) primer pair.<sup>11</sup> Thirty-five cycles of first and second amplifications were performed as follows: denaturation for 30 s at 95 °C, annealing of primers for 1 min at 63 °C, extension for 1 min at 72 °C, and final extension was performed at 72 °C for 7 min. PCR-amplified DNA was purified after agarose gel electrophoresis and amplification products of the second-round PCR were ligated with plasmid and transformed in *Escherichia coli* in a cloning kit (TA Cloning; Invitrogen, Carlsbad, CA). Dideoxynucleotide termination sequencing was performed with the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems Japan, Tokyo). Sequences of 32 independent clones from the sample were determined and analyzed. The pre-treatment analyses by PCR-cloning showed a variant (T54A) resistant to protease inhibitors in 1 of the 32 clones.

We also made a consensus sequence of the NS3 region from the PCR-direct sequences of 35 treatment-naïve Japanese patients with HCV genotype 1b in our hospital (Fig. 2). Compared to the consensus sequence, there were a total of 5 identical substitution variants (V48I, P89S, S122G, R130K, Q195K) within the 32 independent clones from this patient, among which R130K and Q195K were unique to this patient.

### 3. Discussion

Previous studies showed that telaprevir monotherapy for HCV patients with genotype 1 and a high viral load demonstrated substantial antiviral activity, and the median maximum change was -4.77 Log IU/mL with administration at 750 mg every 8 h for 2 weeks.<sup>6,7</sup> In Reesink et al., HCV RNA decreased below the limit of

|             |             |            |            |            |            |       |  |
|-------------|-------------|------------|------------|------------|------------|-------|--|
|             | 1           | 10         | 20         | 30         | 40         | 50    |  |
| CONSENSUS   | APITAYSQQT  | RGLLGCIITS | LTGRDKNQVE | GEVQVSTAT  | QSFLATCVNG |       |  |
| Case clone1 | -----       | -----      | -----      | -----      | -----      | I--   |  |
| Case clone2 | -----       | -----      | -----      | -----      | -----      | I--   |  |
| Case clone3 | ---H---     | -----      | -----      | -----      | -----      | I--   |  |
| Case clone4 | -----       | -----      | -----      | -----      | -----      | I--   |  |
| Case clone5 | -----       | -----      | -----      | -----      | -----      | I--   |  |
|             | 51          |            |            |            |            | 100   |  |
| CONSENSUS   | VCWTVYHGAG  | SKTLGAPKGF | ITQMYTNVDQ | DLVGWQAPPG | ARSLTECTCG |       |  |
| Case clone1 | -----       | -----      | -----      | -----      | S-         | ----- |  |
| Case clone2 | ---F---     | -----      | -----      | -----      | S-         | ----- |  |
| Case clone3 | ---A---     | -----      | -----      | -----      | S-         | ----- |  |
| Case clone4 | -----       | -----      | -----      | -----      | S-         | L---  |  |
| Case clone5 | ---F---     | -----      | -----      | -----      | S-         | ----- |  |
|             | 101         |            | 130        |            |            | 150   |  |
| CONSENSUS   | SSDLYLVTTRH | ADVIVRRRG  | DSRGSLLSPR | FVSYLKGSSG | GPLLCFSGHA |       |  |
| Case clone1 | -----       | -----      | -G-----    | -K-----    | -----      | ----- |  |
| Case clone2 | -----       | -----      | -G-----    | -K-----    | -----      | ----- |  |
| Case clone3 | -----       | -----      | -G-----    | -K-----    | -----      | ----- |  |
| Case clone4 | -----       | -----      | -G-----    | -K-----    | -----      | ----- |  |
| Case clone5 | -----       | -----      | -G-----    | -K-----    | -----      | ----- |  |
|             | 151         |            |            | 195        | 200        |       |  |
| CONSENSUS   | VGIFRAAVCT  | RGVAKAVDFI | EVESMETTMR | SPVFTDNSSP | FAVPQTEQVA |       |  |
| Case clone1 | -----       | -----      | -----      | -----      | ---K---    | 15    |  |
| Case clone2 | -----       | -----      | -----      | -----      | ---K---    | 14    |  |
| Case clone3 | -----       | -----      | -----      | -----      | ---K---    | 1     |  |
| Case clone4 | -----       | -----      | -----      | -----      | ---K---    | 1     |  |
| Case clone5 | -----       | -----      | -----      | -----      | ---K---V   | 1     |  |

Fig. 2. Evolution of the HCV NS3 gene sequence at the start of telaprevir monotherapy. Consensus sequence was made from the HCV RNA of 35 treatment-naïve Japanese patients with genotype 1b in our hospital. The number of clones within each sample of identical amino acid sequences is given on the right at the end of each sequence. Dashes indicate identical amino acid sequences.



detection (10 IU/mL) for 2 patients in the group receiving 750 mg every 8 h.<sup>6</sup> In some patients, however, HCV RNA levels increased between days 7 and 14, and mutations that confer resistance to telaprevir were detected. This trial of telaprevir monotherapy was therefore terminated after 2 weeks, and combination therapy of telaprevir plus PEG-IFN-RBV is now used in the USA and Europe.<sup>8–10</sup> Our case may therefore represent an unusual and possibly serendipitous response to long-term telaprevir monotherapy, and the efficacy of monotherapy remains unclear.

To our knowledge, this is the first report of a patient with CH-C achieving SVR by telaprevir monotherapy, without the use of IFN. Three treatment-naïve Japanese patients were enrolled in our hospital for this phase II trial of telaprevir monotherapy over 24 weeks. Before treatment, the 2 non-SVR patients had a high HCV RNA viral load (>5 Log IU/mL), while the viral load in the SVR patient remained low. Further, while HCV RNA decreased below the limit of detection (10 IU/mL) and negativity of HCV RNA remained until the end of treatment in 2 patients, HCV RNA in the other non-SVR patient reappeared after treatment cessation.

The development of drug resistance has been a challenge for treatment strategies in many viral infections. The high replication rate and the error-prone nature of viral RNA polymerases generate a viral quasi-species from which variants resistant to viral inhibitors can be selected. Recently, Kuntzen et al. reported that viral loads were high in the majority of treatment-naïve patients carrying mutations of protease and polymerase inhibitors.<sup>12</sup> Low viral load may therefore be an important factor for achieving SVR by telaprevir monotherapy.

It has recently been reported that CH-C patients never treated with an NS3-4A protease inhibitor may nevertheless possess variants resistant to protease inhibitors involving the HCV RNA NS3 region.<sup>12–14</sup> While there was a resistant variant (T54A) in this case, this mutation exhibits only low-level resistance,<sup>7</sup> and the number of mutant variants may have been few along with substantial suppression of HCV replication by telaprevir. This may also help to explain the effectiveness of telaprevir in this case.

Moreover, two amino acid substitutions (R130K and Q195K) were unique to this patient. We therefore checked the nucleotide sequence data in the DDBJ/EMBL/GenBank databases and found a previous report by Franco et al. on the R130K substitution (EF013801, EF013863, EF013867, EF013869).<sup>15</sup> Interestingly, although only a minor clone (4% of total) in that study, the viral load of the patient with the R130K substitution was also low (2364 IU/mL). To date, however, the Q195K substitution has not been reported. Their presence in this case may indicate that telaprevir has a stronger antiviral activity against HCV with these substitutions.

The NS3-4A protease targeted by protease inhibitors is required for viral polyprotein processing, an essential step in viral replication, but is also responsible for disrupting IFN responses to the infection.<sup>16</sup> Previous studies have shown that high concentrations of protease inhibitors may restore retinoic acid-inducible gene I (RIG-I) signaling in HCV replicon cells,<sup>16–18</sup> and Liang et al. also recently reported that protease inhibitors could restore interferon regulatory factor 3 (IRF-3) signaling in HCV-infected cells.<sup>19</sup> In our patient, telaprevir may have therefore rescued the NS3-4A-mediated blockade of IRF-3 signaling *in vivo*.

Further studies are required, such as sequencing analyses of the HCV NS3 region, and research into the rescue of IFN- $\beta$  signaling through the RIG-I pathway. It is foreseeable in the future for CH-C patients to be treated by one or a combination of two or more oral drugs with high efficacy and genetic barriers to resistance and low side-effect profiles. Telaprevir may hold promise for being one of these drugs, even if only within a subset of patients, and further studies into telaprevir monotherapy or combination therapy with other oral drugs is therefore warranted. Although still an isolated

response, based on our current molecular understanding of HCV infection and pharmacotherapy, this case suggests that long-term telaprevir monotherapy may be effective in other CH-C patients with genotype 1 and a low viral load.

#### Conflict of interest

The authors have no commercial or other associations that may pose a conflict of interest.

#### Acknowledgments

This study was supported in part by a grant-in-aid from the Ministry of Health, Labor and Welfare, Japan.

#### References

- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–65.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–82.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 2007;46:403–10.
- Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346–55.
- Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3-4A serine protease. *Infect Disord Drug Targets* 2006;6:3–16.
- Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Vliet AV, Rooij JVDWD, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. *Gastroenterology* 2006;131:997–1002.
- Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology* 2007;132:1767–77.
- Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. *J Hepatol* 2008;49:163–9.
- McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;360:1827–38.
- Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goester T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;360:1839–50.
- Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, et al. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. *J Clin Microbiol* 2003;41:2835–41.
- Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. *Hepatology* 2008;48:1769–78.
- Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects. *JID* 2008;198:800–7.
- Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. *Virology* 2008;370:237–45.
- Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. *Hepatology* 2007;45:899–910.
- Foy E, Li K, Wang C, Sumpter Jr R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science* 2003;300:1145–8.
- Johnson CL, Owen DM, Gale Jr M. Functional and therapeutic analysis of hepatitis C virus NS3-4A protease control of antiviral immune defense. *J Biol Chem* 2007;282:10792–803.
- Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, et al. Viral and therapeutic control of IFN- $\beta$  promoter stimulator 1 during hepatitis C virus infection. *Proc Natl Acad Sci USA* 2006;103:6001–6.
- Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. *Gastroenterology* 2008;135:1710–8.

# Influence of Amino-Acid Polymorphism in the Core Protein on Progression of Liver Disease in Patients Infected With Hepatitis C Virus Genotype 1b

Mariko Kobayashi,<sup>1\*</sup> Norio Akuta,<sup>2</sup> Fumitaka Suzuki,<sup>2</sup> Tetsuya Hosaka,<sup>2</sup> Hitomi Sezaki,<sup>2</sup> Masahiro Kobayashi,<sup>2</sup> Yoshiyuki Suzuki,<sup>2</sup> Yasuji Arase,<sup>2</sup> Kenji Ikeda,<sup>2</sup> Sachiyo Watahiki,<sup>1</sup> Rie Mineta,<sup>1</sup> Satomi Iwasaki,<sup>1</sup> Yuzo Miyakawa,<sup>3</sup> and Hiromitsu Kumada<sup>2</sup>

<sup>1</sup>Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan

<sup>2</sup>Department of Hepatology, Toranomon Hospital, Tokyo, Japan

<sup>3</sup>Miyakawa Memorial Research Foundation, Tokyo, Japan

The substitution of amino acid (aa) 70 of arginine for glutamine and/or that of aa91 of leucine for methionine in the core protein in patients infected with hepatitis C virus (HCV) genotype 1b is associated with a poor response to pegylated interferon and ribavirin. Factors influencing these substitutions were sought in 1,097 patients infected with HCV-1b who had not received antiviral treatment. HCV variants with Arg70 and Leu91 (wild-type) decreased, while those with Gln70 and/or Met91 (mutant types) increased with age ( $P < 0.001$ ). Of the 1,097 patients, 464 (42.3%) were infected with the Gln70 variant and the remaining 633 patients with the Arg70 variant. The proportion of patients with the Gln70 variant increased with the severity of liver disease ( $P < 0.001$ ), elevated  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GTP) levels ( $P < 0.001$ ) and a decrease in platelet count ( $P = 0.008$ ). In univariate analysis patients with hepatocellular carcinoma, elevated aspartate aminotransferase (AST  $\geq 58$  IU/L) and  $\gamma$ -GTP ( $\geq 61$  IU/L), and decreased albumin levels ( $< 3.9$  g/dl) were more frequent in the patients with the Gln70 variant than the Arg70 variant ( $P = 0.003$ ,  $0.005$ ,  $< 0.001$ , and  $0.031$ , respectively). In multivariate analysis HCC (odds ratio 1.829 [95% confidence interval 1.147–2.917]) and  $\gamma$ -GTP  $\geq 61$  IU/L (1.647 [1.268–2.139]) increased the risk for the Gln70 variant. In conclusion, the substitution of amino aa70 of Arg for Gln in patients infected with HCV-1b increases with age, and it is associated with severe liver disease accompanied by elevated AST and  $\gamma$ -GTP levels, as well as the development of hepatocellular carcinoma. **J. Med. Virol.** 82:41–48, 2010. © 2009 Wiley-Liss, Inc.

**KEY WORDS:** cirrhosis; core protein; hepatitis C; hepatocellular carcinoma; interferon; ribavirin

## INTRODUCTION

Worldwide, an estimated 170 million people are infected with hepatitis C virus (HCV) persistently [Cohen, 1999]. Decompensated cirrhosis and hepatocellular carcinoma (HCC) can develop in about 30% of patients infected with HCV [Alberti et al., 1999; Seeff, 2002]. HCV has six major genotypes and dozens of subgenotypes, and they have distinct geographic distributions and are associated with the progression of liver disease [Simmonds, 1995]. Host and virological factors can influence the severity of liver disease and the response to antiviral treatment. HCV infection in the childhood and women runs a milder course than that in adulthood and men, and the intake of alcohol accelerates the progression of liver disease [Poynard et al., 1997; Kenny-Walsh, 1999; Vogt et al., 1999; Wiese et al., 2000]. Genotypes 1 and 4 aggravate liver disease and decrease the response to antiviral treatment, in comparison with genotypes 2, 3, and 6 [Tsubota et al., 1994; Hui et al., 2003; Hadziyannis et al., 2004; Legrand-Abravanel et al., 2005; Yuen and Lai, 2006]. High levels of HCV RNA in the serum can induce severe liver disease and decrease treatment response [Tsubota et al., 1994].

In Japan, genotype 1b in a high viral load ( $> 100$  KIU/ml) accounts for  $> 70\%$  of HCV infection, and decreases the treatment response in patients with chronic hepatitis C [Kumada et al., 2006]. Even with pegylated interferon (PEG-IFN) combined with ribavirin, the sustained virological response for longer than 24 weeks after the withdrawal of treatment is achieved merely in

Grant sponsor: Ministry of Health, Labour and Welfare of Japan.

\*Correspondence to: Mariko Kobayashi, BS, Research Institute for Hepatology, Toranomon Hospital, 1-3-1, Kajigaya, Takatsuku, Kawasaki City 213-8587, Japan.

E-mail: vj7m-kbys@asahi-net.or.jp

Accepted 18 July 2009

DOI 10.1002/jmv.21629

Published online in Wiley InterScience  
(www.interscience.wiley.com)

50% of the patients with HCV-1b in high levels [Manns et al., 2001; Fried et al., 2002]. It is necessary to predict the response to PEG-IFN/ribavirin before the start of antiviral therapy, to avoid severe side-effects in the patients who will barely gain sustained virological response.

The core protein of HCV is coded for by the C gene, and consists of 191 amino acids (aa) [Rosenberg, 2001]. Although the core protein is conserved better than the other structural and non-structural proteins of HCV, polymorphisms of core protein are known, and they influence the response to antiviral treatment. In patients infected with HCV-1b, for example, the substitution of arginine at position 70 (Arg70) for glutamine (Gln70) and that of leucine at position 91 (Leu91) for methionine (Met70) decrease sustained virological response in the patients with chronic hepatitis C who are treated with PEG-IFN/ribavirin and increase the development of HCC [Akuta et al., 2007a,b,d, 2008].

In the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo, the amino-acid sequence of the core-protein was determined in 1,079 patients infected with HCV-1b who had not received antiviral treatment. The substitution of Arg70 for Gln70 and that of Leu91 or Met91 were correlated with the age at presentation, liver function tests and the severity of liver disease. Based on the results obtained, Gln70 would contribute to the progression of chronic hepatitis C.

## MATERIALS AND METHODS

### Patients

During 1966–2008, 1,097 patients infected with HCV-1b visited the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo. They were: (1) negative for hepatitis B surface antigen by radioimmunoassay (Dainabot, Tokyo, Japan) or antibody to human immunodeficiency virus type-1; (2) positive for anti-HCV by a third-generation enzyme immunoassay (Chiron Corp., Emeryville, CA) and HCV RNA by the polymerase chain reaction (PCR) (Cobas Amplicor HCV Monitor ver.2.0, Roche Diagnostics, Tokyo, Japan); (3) infected with HCV genotype 1b but not with other genotypes; (4) without previous antiviral treatment; (5) without other forms of hepatitis, including hemochromatosis, Wilson's disease, primary biliary cirrhosis, alcoholic liver disease and autoimmune liver disease; and (6) had serum samples stored at  $-80^{\circ}\text{C}$ . Of the 1,097 patients, 778 (70.9%) had chronic hepatitis, 221 (20.1%) cirrhosis, and 98 (8.9%) HCC. Amino acids in the core protein at positions 70 and 91 were determined, and were correlated with liver disease and biochemical and virological markers. Informed consent was obtained from each patient in this study, and the protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected by approval by Ethic Committee of the institution.

## Histopathological Diagnoses of Liver Disease

Liver biopsy was performed under laparoscopy by a modified Vim Silverman needle (Tohoku University style, Kakinuma Factory, Tokyo). The sample was fixed in 10% formalin, and was stained with hematoxylin and eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff. It contained at least six portal areas. The pathological diagnosis was made by one of the authors (H.K.) who was blinded to the clinical data. Chronic hepatitis was diagnosed based on the scoring system of Desmet et al. [1994]. Cirrhosis was diagnosed by imaging on ultrasonography (US), computed tomography (CT), or magnetic resonance imaging (MRI). HCC was diagnosed by US and/or CT. Angiography was performed when HCC was strongly suspected by US, CT, MRI, or liver biopsy. An increasing trend of tumor markers was taken into consideration for the diagnosis of HCC.

## Determination of Amino-Acid Substitutions in the Core Protein

Amino acid (aa) at position 70 of Arg or Gln and aa91 of Leu or Met were determined by PCR with primers specific for each of them [Okamoto et al., 2007]. It is highly reproducible, and has a sensitivity of 94.4% in the determination of aa70 or aa91 in samples with HCV RNA titers  $>10$  KIU/ml. The concordance of the results of this method with those of direct sequencing reached 97.1%. Amino acids at positions 70 and 91 were confirmed by direct sequencing of most samples [Akuta et al., 2005].

## Statistical Analysis

Changes of Arg70/Leu91 (wild-type) and Gln70 and/or Met91 (mutant types) with age were analyzed by the Cochran–Armitage trend test (SAS version 9.1.3; SAS Institute, Inc., Cary, NC). Frequencies were compared between groups by the Kruskal–Wallis test and Fisher's exact test. Univariate and multivariate logistic regression analyses were used for the evaluation of factors independently associated with the substitution of aa70. They included the following ten variables: age, sex, liver disease, platelet count, hemoglobin, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT),  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GTP), and substitution of aa at position 91 in the core protein. Each variable was transformed into categorical data consisting of two simple ordinal numbers for univariate and multivariate analyses. Variables that achieved statistical significance on univariate analysis were tested by the multivariate Cox proportional hazard model to identify independent factors. Statistical comparisons were performed using SPSS ver.11.0 (SPSS, Inc., Chicago, IL). A *P*-value  $<0.05$  by the two-tailed test was considered significant.



## RESULTS

## Clinical and Virological Characteristics of the 1,097 Patients Who Were Infected With HCV-1b

Table I lists the baseline characteristics of the 1,097 patients who were infected with HCV-1b and had not received antiviral treatment. They had the median age of 60 years and included 590 (53.8%) men. The median transaminase levels were elevated, and alpha-fetoprotein was within the normal limit ( $<10 \mu\text{g/L}$ ). The majority of the patients (70.9%) had chronic hepatitis, while HCC had developed in 8.9% of the patients. Amino acids at positions 70 and 91 in the core protein were both the wild-type (Arg70 and Leu91) in 37.6% of them, and both mutant types (Gln70 and Met91) in 16.4%. The Gln70 variant was detected in 464 of the 1,097 (42.3%) patients.

## The Prevalence of Amino-Acid Substitutions Stratified by Age and Sex

The 1,097 patients infected with HCV-1b were classified into three age groups, and the prevalence of Arg70/Leu91 (wild-type) and that of Gln70 and/or Met91 (mutant types) were compared (Fig. 1). Arg70/Leu91 decreased with age by trend analysis, from 63.6% in the patients aged  $\leq 30$  years to 36.6% in those  $\geq 41$  years ( $P < 0.001$  by the Cochran–Armitage trend test). Table II lists the prevalence of the Gln70 variant in men and women stratified by the age. There were no sex differences in the prevalence of the Gln70 variant.

## The Prevalence of the Gln70 Variant in Patients With Different Liver Diseases

Figure 2 compares the prevalence of the Gln70 variant among patients infected with HCV-1b who presented with different liver diseases at the baseline. The prevalence of the Gln70 variant increased with the progression of liver disease from chronic hepatitis

TABLE I. Clinical and Virological Characteristics of the 1,097 Patients Who Were Infected With Hepatitis C Virus of Genotype 1b

|   |                 |
|---|-----------------|
| Age (years)                             | 60 (19–83)      |
| Men                                     | 590 (53.8%)     |
| Follow-up period (years)                | 8 (3–28)        |
| Hemoglobin (g/dl)                       | 14.0 (4.5–26.8) |
| Platelets ( $\times 10^3/\text{mm}^3$ ) | 15.4 (2.0–34.1) |
| Aspartate aminotransferase (IU/L)       | 58 (8–617)      |
| Alanine aminotransferase (IU/L)         | 69 (6–776)      |
| Alpha-fetoprotein ( $\mu\text{g/L}$ )   | 6 (2–65,700)    |
| Liver disease                           |                 |
| Chronic hepatitis                       | 778 (70.9%)     |
| Cirrhosis                               | 221 (20.1%)     |
| Hepatocellular carcinoma                | 98 (8.9%)       |
| Amino acids in the core protein         |                 |
| Arg70/Leu91 (double wild-type)          | 412 (37.6%)     |
| Gln70/Leu91 (mutant type)               | 284 (25.9%)     |
| Arg70/Met91 (mutant type)               | 221 (20.1%)     |
| Gln70/Met91 (double mutant type)        | 180 (16.4%)     |

Values are the median with range in parentheses or the number with percentage in parentheses.




Fig. 1. The age-specific prevalence of Gln70 in treatment-naive patients infected with HCV-1b.

(32.6%) to cirrhosis (43.0%) and HCC (53.1%) ( $P < 0.001$  by the Kruskal–Wallis test). In patients with cirrhosis, the 126 patients with the Arg70 variant were aged with the mean of 62 years (range: 32–78 years) in comparison with the 95 patients with the Gln70 variant who were aged 59 years (25–80). In patients with HCC, the 47 patients with the Arg70 variant were aged with the mean of 66 years (range: 37–81 years) in comparison with the 51 patients with the Gln70 variant who were aged 66 years (46–78).

TABLE II. Frequency of Gln70 in the Core Protein in Patients Infected With HCV-1b Stratified by Age and Sex

| Age (years) | Men             | Women           | Differences |
|-------------|-----------------|-----------------|-------------|
| 19–30       | 23.5% (4/17)    | 20% (1/5)       | 1.0         |
| 31–40       | 34.1% (14/41)   | 38.9% (7/18)    | 0.773       |
| 41–50       | 37.2% (45/121)  | 40% (14/35)     | 0.763       |
| 51–60       | 39.1% (72/184)  | 40.1% (63/157)  | 0.912       |
| 61–70       | 36.0% (62/172)  | 30.1% (74/246)  | 0.205       |
| 70–83       | 45.5% (25/55)   | 43.5% (20/46)   | 0.842       |
| Total       | 37.6% (222/590) | 35.3% (179/507) | 0.451       |




Fig. 2. The prevalence of the Gln70 variant among patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.




Fig. 3. The prevalence of the Gln70 variant among patients with different  $\gamma$ -GTP levels.

#### The Influence of $\gamma$ -GTP Levels on the Prevalence of the Gln70 Variant

The prevalence of Gln70 was compared among patients with different  $\gamma$ -GTP levels at the baseline (Fig. 3). The prevalence of the Gln70 variant increased in parallel with the  $\gamma$ -GTP levels from 29.0% to 49.6% ( $P < 0.001$  by the Kruskal–Wallis test).

#### The Influence of Platelet Count on the Prevalence of the Gln70 Variant

The prevalence of the Gln70 variant was compared among three groups of patients with various platelet counts at the baseline (Fig. 4). The prevalence of the Gln70 variant increased as the platelet count decreased ( $P = 0.008$  by the Kruskal–Wallis test).

#### Factors Associated With the Gln70 Variant in Patients Infected with HCV-1b

Since the Gln70 variant, in comparison with the Arg70 variant, aggravated liver disease in patients infected with HCV-1b (Figs. 2–4), ten factors were evaluated for the association with the Gln70 variant by the univariate analysis (Table III); the cut-off value was

set at the median of studied patients. Among them, HCC, elevated levels of AST ( $\geq 58$  IU/L) and  $\gamma$ -GTP ( $> 61$  U/L), as well as decreased albumin concentration ( $< 3.9$  g/dl), were associated with the Gln70 variant ( $P = 0.003$ ,  $0.005$ ,  $< 0.001$ , and  $0.031$ , respectively). A similar analysis was performed for the substitution of Leu91 for Met91 (Table IV). Except for the association with the substitution of Arg70 for Gln70, the Met91 variant had no influence on any variable examined.

Two factors associated independently with the Gln70 variant were identified by the multivariate analysis (Table V). The risk for the Gln70 variant was increased by HCC (odds ratio 1.829 [95% confidence interval 1.147–2.917],  $P = 0.011$ ) and  $\gamma$ -GTP  $\geq 61$  IU/L (1.647 [1.268–2.139],  $P < 0.001$ ).

#### DISCUSSION

The response to PEG-IFN and ribavirin is influenced by genotypes and viral load, and is poorest in patients with HCV-1b in high HCV RNA levels [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004]. The prediction of sustained virological response would circumvent side-effects and costs in non-responders. Amino-acid substitutions in the core protein are useful




Fig. 4. The prevalence of the Gln70 among three groups of patients with different platelet counts.

for predicting the non-response in patients infected with HCV-1b. The substitution of Arg70 for Gln70 in the prototype sequence of HCV-1b [Kato et al., 1990] and/or that of Leu91 for Met91 can predict the non-response to

IFN-based treatment [Akuta et al., 2005, 2006, 2007c,d]. It has been beyond the scope of previous studies, however, whether or not these amino-acid substitutions influence the progression of hepatitis C in the patients who have not received antiviral treatment. The availability of pre-treatment sera from many patients with chronic hepatitis C permitted the evaluation of the influence of aa substitutions in the core protein on the progression of liver disease without therapeutic intervention.

First, the prevalence of the Gln70 variant increased with the age of patients until they had reached 50 years (Fig. 1). It is not certain if HCV-1b with Arg70 underwent a point mutation for Gln70 (G-to-A at nucleotide 209), or these amino-acid residues were present in HCV-1b strains prevalent at the time of infection. Follow-up of patients for aa substitutions will resolve this issue. Another possibility for this difference would be a selection bias. If the patients with the Arg90 variant fare better than those with the Gln70 variant, they would not develop liver disease severe enough to visit hospital.

Secondly, the patients infected with HCV-1b with Gln70 increased in parallel with  $\gamma$ -GTP levels and the severity of liver disease from chronic hepatitis to cirrhosis and HCC, as well as with a decrease in platelet count (Figs. 2-4). Since the Met91 variant did not make such difference, the aggravation of liver disease would have been due to the Gln70 variant, but not to the Met91 variant. Increases in the  $\gamma$ -GTP level may have been related to the development of HCC;  $\gamma$ -GTP has been proposed as a sensitive marker of cirrhosis and HCC [Penn and Worthington, 1983]. Decreased platelet counts have been associated with HCC [Ikeda et al., 2001; Lu et al., 2006; Kumada et al., 2009]. Although the proportion of the Gln70 variant increases with the severity of liver disease (Fig. 2), the median age of patients with cirrhosis or HCC did not differ between the patients with the Arg70 variant and Gln70 variant who

TABLE III. Factors Associated With the Substitution of aa70 of Arginine for Glutamine in the Core Protein in 1,097 Patients Infected With HCV Genotype1b by Univariate Analysis

| Factor                                       | Category      | Gln70           | P-value |
|--|---------------|-----------------|---------|
| Sex  | 1: Male       | 38.6% (228/590) | 0.663   |
|  | 2: Female     | 37.3% (189/507) |         |
| Age (years)                                  | 1: <60        | 40.6% (219/540) | 0.093   |
|  | 2: $\geq 60$  | 35.5% (198/557) |         |
| AST (IU/L)                                   | 1: <58        | 33.9% (184/543) | 0.005   |
|  | 2: $\geq 58$  | 42.2% (234/554) |         |
| ALT (IU/L)                                   | 1: <75        | 36.9% (213/578) | 0.376   |
|  | 2: $\geq 75$  | 39.3% (204/519) |         |
| Albumin (g/dl)                               | 1: <3.9       | 42.5% (194/457) | 0.031   |
|  | 2: $\geq 3.9$ | 35.8% (229/640) |         |
| $\gamma$ -GTP (IU/L)                         | 1: <61        | 29.0% (163/562) | <0.001  |
|  | 2: $\geq 61$  | 44.4% (238/535) |         |
| Hemoglobin (g/dl)                            | 1: <14        | 35.1% (176/501) | 0.083   |
|  | 2: $\geq 14$  | 40.4% (241/596) |         |
| Platelet count ( $\times 10^3/\text{mm}^3$ ) | 1: <150       | 39.9% (207/519) | 0.253   |
|  | 2: $\geq 150$ | 36.3% (210/578) |         |
| Hepatocellular carcinoma                     | 1: No         | 36.6% (366/999) | 0.003   |
|  | 2: Yes        | 53.1% (52/98)   |         |
| Substitutions of core aa91                   | 1: Leucine    | 35.6% (227/638) | 0.051   |
|  | 2: Methionine | 41.4% (190/459) |         |



TABLE IV. Factors Associated With the Substitution of aa91 of Leucine for Methionine in the Core Protein in 1,097 Patients Infected With HCV Genotype1b by Univariate Analysis

| Factor                                       | Category     | Met91           | P-value |
|--|--------------|-----------------|---------|
| Sex  | 1: Male      | 40.8% (241/590) | 0.500   |
|  | 2: Female    | 43.0% (218/507) |         |
| Age (years)                                  | 1: <60       | 43.5% (235/540) | 0.271   |
|  | 2: ≥60       | 40.2% (220/517) |         |
| AST (IU/L)                                   | 1: <58       | 43.6% (234/537) | 0.196   |
|  | 2: ≥58       | 39.7% (217/547) |         |
| ALT (IU/L)                                   | 1: <75       | 42.4% (238/561) | 0.618   |
|  | 2: ≥75       | 40.8% (205/502) |         |
| Albumin (g/dl)                               | 1: <3.9      | 42.0% (177/421) | 0.797   |
|  | 2: ≥3.9      | 41.2% (249/604) |         |
| γ-GTP (IU/L)                                 | 1: <61       | 40.4% (237/586) | 0.327   |
|  | 2: ≥61       | 43.4% (222/511) |         |
| Hemoglobin (g/dl)                            | 1: <14       | 40.8% (193/473) | 0.658   |
|  | 2: ≥14       | 42.3% (240/567) |         |
| Platelet count ( $\times 10^3/\text{mm}^3$ ) | 1: <150      | 40.5% (202/499) | 0.454   |
|  | 2: ≥150      | 42.9% (240/559) |         |
| Hepatocellular carcinoma                     | 1: No        | 42.3% (423/999) | 0.334   |
|  | 2: Yes       | 36.7% (36/98)   |         |
| Substitutions of core aa71                   | 1: Arginine  | 49.0% (269/680) | 0.051   |
|  | 2: Glutamine | 45.6% (190/417) |         |

had cirrhosis (62 years vs. 59 years) of HCC (66 years vs. 66 years). This would indicate a possibility that the Gln70 variant would be a factor for the aggravation of liver disease that might be independent of age.

The distinct capacity of Gln70 and Met91 for decreasing the response to combined treatment in patients infected with HCV-1b was proposed in a recent study [Okanoue et al., 2008]. The Gln70 variant decreased sustained virological response, while the Met91 variant did not, although the Met91 variant reduced the rate of rapid virological response within 4 weeks after the start of therapy. The role of the Gln70 variant greater than that of the Met91 variant in the progression of liver disease has been confirmed in this study (Tables III and IV). In the multivariate analysis, the risk for Gln70 was increased by HCC (odds ratio 1.829 [95% confidence interval 1.147–2.917]) and  $\gamma$ -GTP  $\geq 61$  U/L (1.647 [1.268–2.139]). The Gln70 variant would aggravate liver disease toward the development of HCC in patients infected with HCV-1b who have not received antiviral treatment.

It would be a matter of conjecture how the Gln70 variant influences the severity of liver disease. Previous suggestions for a reduced response of patients with the Gln70 variant were confined to interaction of the core protein with IFN receptors and IFN-signaling pathways [Alexander, 2002; Blindenbacher et al., 2003; Bode et al., 2003]; these studies were restricted to patients receiving

IFN-based treatments [Akuta et al., 2007a,b,d, 2008]. The ability of the Gln70 variant for accelerating the progression of liver disease, in the absence of exogenous IFN, has changed this issue into a wider perspective. There still remains a possibility, however, that the Gln70 variant would interact with the endogenous IFN induced by HCV infection, and aggravate liver disease.

Another possibility may be the cytotoxic T-cell (CTL) response, as has been demonstrated for the pathogenesis of chronic hepatitis B [Chisari and Ferrari, 1995]. Since both hepatitis B virus (HBV) and HCV do not have a cytopathic capacity, hepatitis B and C would be mediated by immune responses directed at viral proteins. Amino-acid sequences bearing a CTL epitope restricted by the MHC class-I are demonstrated in the HBV core protein [Bertoletti et al., 1993; Bertoletti and Gehring, 2006], and are implicated in liver disease in the patients with the HLA-2 phenotype [Penna et al., 1991; Bertoletti et al., 1994]. It is tempting to speculate that the substitution of Arg70 for Gln70 might generate a CTL epitope and stimulate cytotoxic lymphocytes toward inflammation of the liver [Kita et al., 1993; Jackson et al., 1999].

In conclusion, amino-acid substitutions in the core protein influence the progression of liver disease, and the Gln70 variant aggravates hepatic inflammation and increases the risk for HCC in the patients who have not received antiviral treatment. The ability of the Gln70

TABLE V. Factors Associated with the Substitution of aa70 of Arginine for Glutamine in the Core Protein in 1,097 Patients Infected with HCV Genotype1b by Multivariate Analysis

| Factor                   | Category | Odds ratio (95%CI)  | P-value |
|--------------------------|----------|---------------------|---------|
| Hepatocellular carcinoma | 1: No    | 1                   | 0.011   |
|                          | 2: Yes   | 1.829 (1.147–2.917) |         |
| γ-GTP (IU/L)             | 1: <61   | 1                   | <0.001  |
|                          | 2: ≥61   | 1.647 (1.268–2.139) |         |

variant to aggravate liver disease, in the absence of exogenous IFN, would lend further support on its capacity of predicting sustained virological response before the start of therapy. It is possible that mechanisms other than the resistance to IFN, such as cytotoxic T-cell responses, might be involved in an increased pathogenetic potential of HCV-1b with Gln70.

## REFERENCES

- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372–380.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Arase Y, Ikeda K, Kumada H. 2006. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *J Med Virol* 78:83–90.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *Hepatology* 46:1357–1364.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 46:403–410.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007c. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 79:1686–1695.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007d. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. *Intervirology* 50:361–368.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2008. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. *J Med Virol* 80:1354–1362.
- Alberti A, Chemello L, Benvenuto L. 1999. Natural history of hepatitis C. *J Hepatol* 31:S17–S24.
2002. Suppressors of cytokine signalling (SOCS) in the immune system. *Nat Rev Immunol* 2:410–416.
- Bertoletti A, Gehring AJ. 2006. The immune response during hepatitis B virus infection. *J Gen Virol* 87:1439–1449.
- Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, Schlicht HJ, Vitello A, Chesnut RC, Fiaccadori F, Ferrari C. 1993. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. *J Virol* 67:2376–2380.
- Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, Giuberti T, Fiaccadori F, Ferrari C. 1994. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. *J Exp Med* 180:933–943.
- Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. 2003. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. *Gastroenterology* 124:1465–1475.
- Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Haussinger D. 2003. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. *FASEB J* 17:488–490.
- Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol* 13:29–60.
- Cohen J. 1999. The scientific challenge of hepatitis C. *Science* 285:26–30.
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. *Hepatology* 19:1513–1520.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.
- Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140:346–355.
- Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. 2003. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1. *J Infect Dis* 187:1071–1074.
- Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H. 2001. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. *J Gastroenterol Hepatol* 16:406–415.
- Jackson M, Smith B, Bevitt DJ, Steward M, Toms GL, Bassendine MF, Diamond AG. 1999. Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. *J Med Virol* 58:239–246.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528.
- Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *N Engl J Med* 340:1228–1233.
- Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H, Nakamura I, Yazaki Y, Imawari M. 1993. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. *Hepatology* 18:1039–1044.
- Kumada T, Toyoda H, Honda T, Kuzuya T, Katano Y, Nakano I, Goto H. 2006. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. *Intervirology* 49:112–118.
- Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. 2009. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. *J Hepatol* 50:729–735.
- Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *J Med Virol* 77:66–69.
- Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Huang CH. 2006. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. *Cancer* 107:2212–2222.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. *Lancet* 358:958–965.
- Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. 2007. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. *J Virol Methods* 141:1–6.
- Okanou T, Itoh Y, Yotsuyanagi H, Tanaka E, Yoshioka K, Izumi N, Kumada H. 2008. Substitution of core amino acid 91 lowers rapid virological response and substitution of amino acid 70 lowers sustained virological response to peginterferon alfa-2b plus ribavirin in chronic hepatitis C patients with genotype 1b—Nationwide Study (Abstract). *Hepatology* 48:868A.
- Penn R, Worthington DJ. 1983. Is serum gamma-glutamyltransferase a misleading test? *Br Med J* 286:531–535.
- Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. 1991. Cytotoxic T lymphocytes recognize an

- HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. *J Exp Med* 174:1565–1570.
- Poynard T, Bedossa P, Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 349:825–832.
- Rosenberg S. 2001. Recent advances in the molecular biology of hepatitis C virus. *J Mol Biol* 313:451–464.
- Seeff LB. 2002. Natural history of chronic hepatitis C. *Hepatology* 36:S35–S46.
- Simmonds P. 1995. Variability of hepatitis C virus. *Hepatology* 21:570–583.
- Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. 1994. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. *Hepatology* 19:1088–1094.
- Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. 1999. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med* 341:866–870.
- Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. 2000. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. *Hepatology* 32:91–96.
- Yuen MF, Lai CL. 2006. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. *Intervirology* 49:96–98.

## Original Article

## Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants

Tetsuya Hosaka,<sup>1</sup> Fumitaka Suzuki,<sup>1</sup> Masahiro Kobayashi,<sup>1</sup> Miharuru Hirakawa,<sup>1</sup> Yusuke Kawamura,<sup>1</sup> Hiromi Yastuji,<sup>1</sup> Hitomi Sezaki,<sup>1</sup> Norio Akuta,<sup>1</sup> Yoshiyuki Suzuki,<sup>1</sup> Satoshi Saitoh,<sup>1</sup> Yasuji Arase,<sup>1</sup> Kenji Ikeda,<sup>1</sup> Yuzo Miyakawa<sup>2</sup> and Hiromitsu Kumada<sup>1</sup>

<sup>1</sup>Department of Hepatology, Toranomon Hospital, and <sup>2</sup>Miyakawa Memorial Research Foundation, Tokyo, Japan

**Aim:** To identify factors for the development of hepatocellular carcinoma (HCC) in the patients who receive adefovir add-on lamivudine for treatment of lamivudine-resistant hepatitis B virus (HBV) mutants.

**Methods:** A total of 247 patients who developed lamivudine-resistant HBV mutants, with an increase of HBV DNA  $\geq 1$  log copies/mL, received adefovir dipivoxil 10 mg add-on lamivudine 100 mg daily during a median of 115 weeks (range: 25–282 weeks). They were followed for the development of HCC by imaging modalities every 3–6 months.

**Results:** HCC developed in 18 of the 247 (7.3%) patients. Eight factors were in significant association with the development of HCC by the univariate analysis. They included age, cirrhosis, platelet counts, levels of bilirubin, aspartate aminotransferase (AST), alanine aminotransferase and  $\alpha$ -fetoprotein, as well as YMDD mutants at the start of

adefovir dipivoxil. By the multivariate analysis, AST levels, YIDD mutants, cirrhosis and age were independent factors for the development of HCC. By the Kaplan-Meier analysis, AST levels  $\geq 70$  IU/L, YIDD mutants, cirrhosis and age  $\geq 50$  years increased the risk of HCC ( $P = 0.018$ ,  $P = 0.035$ ,  $P = 0.002$  and  $P = 0.014$ , respectively). HCC developed more frequently in the patients with than without cirrhosis at the start of adefovir (10/59 [16.9%] vs. 8/188 [4.3%],  $P = 0.002$ ).

**Conclusion:** HCC can develop in cirrhotic patients receiving adefovir add-on lamivudine. Hence, the patients with baseline AST  $\geq 70$  IU/L and YIDD mutants would need to be monitored closely for HCC.

**Key words:** adefovir dipivoxil, chronic hepatitis B, hepatitis B virus, hepatocellular carcinoma, lamivudine, rescue therapy

## INTRODUCTION

WORLDWIDE, AN ESTIMATED 400 million people are infected with hepatitis B virus (HBV) persistently, and one million die of decompensated cirrhosis and/or hepatocellular carcinoma (HCC) annually.<sup>1,2</sup> Interferon (IFN) was introduced for treatment of chronic hepatitis B, and it has been replaced for pegylated-IFN.<sup>3</sup> Due to substantial side-effects and requirement for injection, however, IFN-based therapies are not favored.

In 1998, lamivudine was approved as the first nucleot(s)ide analogue for treatment of chronic hepatitis B,<sup>4</sup> and then adefovir in 2002.<sup>5</sup> Due to its lower costs and

safety records, lamivudine has gained a wide popularity for treatment of chronic hepatitis B. However, drug-resistant mutants arise in parallel with the duration of lamivudine, in 12.5% after 1 year, in 43.8% after 3 years, and 62.5–70.2% after 5 years.<sup>6,7</sup> For preventing breakthrough hepatitis induced by lamivudine-resistant HBV mutants, additional adefovir dipivoxil 10 mg daily has been recommended;<sup>8,9</sup> it is more effective than switching to adefovir monotherapy and has fewer chances of developing drug-resistant mutants.<sup>10,11</sup>

Since 1995, 930 patients with chronic hepatitis have been treated with lamivudine in the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo.<sup>12</sup> HBV mutants with mutations in the thymosine-methionine-aspartic acid-aspartic acid (YMDD) motif elicited in the 247 (26.5%) patients, and they started to receive additional adefovir since December, 2002.<sup>13,14</sup> However, HCC developed in 18 (7.3%) of them during the combination therapy for 25–282 weeks; HCC has

Correspondence: Dr Tetsuya Hosaka, Department of Hepatology, Toranomon Hospital, 1-3-1, Kajigaya, Takatsu-ku, Kawasaki 213-8587, Japan. Email: hosa-p@toranomon.gr.jp  
Received 25 April 2009; revision 6 June 2009; accepted 9 June 2009.